Pfizer (NYSE: PFE) finds itself at a crossroads that dividend investors know well. The stock has been beaten up, the yield looks attractive, and the company is telling a compelling growth story. But is it real?
With 96 pipeline candidates, including 31 in Phase 3, a freshly beaten-down share price, and a Q1 2026 earnings report that actually surprised to the upside, there’s a genuine debate to be had here. This isn’t about whether Pfizer is a bad company. Broadly focused, the question is whether there’s enough credible growth ahead to justify buying PFE today for its dividend, with the expectation that the pipeline eventually does the heavy lifting for stock price and payout growth.
Q1 2026 Earnings: More Good Than Bad, But Not Without Asterisks
Pfizer’s first quarter of 2026 was, by most measures, better than expected. Revenue came in at $14.5 billion, up 2% operationally from a year ago. The more interesting number was the 22% operational revenue growth from recently launched and acquired products. Strip out the still-declining COVID franchise (Comirnaty fell 59% and Paxlovid dropped 63% operationally), and the rest of the business grew 7%.
- PADCEV was up 39%
- NURTC was up 41%
- Lorbrena was up 32%
- Oncology biosimilars surged 52%
The takeaway is that the Seagen acquisition and the Biohaven deal are proving their worth. NURTEC is showing impressive momentum in the treatment of migraines.
Now for the asterisks. Adjusted diluted EPS of $0.75 was down 19% from $0.92 a year ago. A chunk of that was timing, specifically, a favorable royalty adjustment in Q1 2025 didn’t repeat. But R&D spending also jumped 11% as Pfizer pours money into oncology and obesity candidates. Cost of sales as a percentage of revenue crept higher as well.
The company also confirmed it anticipates roughly $1.5 billion in revenue headwinds this year from generic and biosimilar competition on products losing patent protection. None of these are catastrophic, but they’re real headwinds that investors should factor into their modeling of near-term earnings power.
That said, Pfizer affirmed its full-year guidance of $59.5 to $62.5 billion in revenue with adjusted diluted EPS of $2.80 to $3.00. That signals management has confidence in the rest of the year.
The Pipeline Story: Compelling, But Patience Required
Here’s where the bull case is interesting, but where you have to be honest with yourself about timelines. Pfizer has 96 pipeline candidates with 31 in Phase 3 and several already at the registration stage. That is a legitimate late-stage pipeline, not a collection of early-stage lottery tickets.
The near-term catalysts are real
- PADCEV has already received priority FDA review for expanded use in muscle-invasive bladder cancer, with a decision targeted for August 2026.
- ELREXFIO just posted strong Phase 3 results in multiple myeloma.
- TUKYSA is advancing toward a new approval in HER2-positive breast cancer maintenance.
- The Lyme disease vaccine candidate, while it didn’t hit its pre-specified statistical criterion in the Phase 3 VALOR trial, was still 73-74% efficacious, and Pfizer is planning regulatory submissions.
These aren’t moonshots — they’re programs with real data behind them.
The obesity angle is the wildcard everyone is watching. Pfizer’s GLP-1 candidate berobenatide (from the Metsera acquisition) has 10 pivotal studies planned for 2026. Monthly dosing could be a meaningful differentiator in a market dominated by weekly injections.
But berobenatide is still in Phase 3 — it’s not approved, not generating revenue, and realistically won’t be a commercial driver until 2028 at the earliest, assuming trial success and a reasonable regulatory timeline. The combo candidate with an amylin analog is at an even earlier stage. So if you’re buying Pfizer today for its obesity optionality, you’re buying a call option that likely doesn’t pay off for several years.
Pfizer itself is transparent about this: their stated goal is a high single-digit 5-year revenue CAGR from year-end 2028 to year-end 2033. That’s a post-2028 growth story. The bridge to get there — navigating loss-of-exclusivity headwinds on several products while the new pipeline matures — is the uncomfortable middle chapter for current shareholders.
The Chart: A Potential Floor, But Overhead Resistance Is Real
For investors dollar-cost averaging into PFE, the technical picture actually offers a modestly encouraging backdrop, even if it shouldn’t be the primary thesis. The stock has been in a fairly defined range since mid-2025, trading mostly between $23 and $29, and the recent pullback from April highs near $28.50 back toward the $25.75–$26 area has brought it close to the 200-day moving average (currently around $25.80). That level has acted as support on prior tests, and the stock appears to be finding a footing there again.
The 50-day moving average at $26.81 sits just overhead as near-term resistance, and the stock is currently trading below it. That’s not ideal for momentum investors, but for someone building a position over time, buying near the 200-day with a long time horizon is historically a reasonable entry discipline.
The Single Biggest Risk: Patent Cliffs and the Coverage Gap
If there’s one thing that should give a prospective PFE buyer pause, it’s the 2026–2028 exclusivity window. Pfizer is heading into a period where several meaningful products face generic or biosimilar competition. The Vyndamax patent settlement is actually good news — it extended effective exclusivity to mid-2031, which was a significant positive legal development disclosed this quarter — but other products across the portfolio face pressure.
The company has already baked in $1.5 billion of revenue impact this year alone. The pipeline products that are supposed to fill the gap are mostly 2028 and beyond stories. That middle stretch of 2026 to 2028 is where the dividend coverage argument gets tested most directly.
Pfizer paid out $2.4 billion in dividends in Q1 alone, or $0.43 per share. With adjusted EPS guided at $2.80–$3.00 for the full year, the math on dividend coverage is workable but not comfortable. There isn’t much cushion. If a couple of pipeline readouts go the wrong way, or if COVID revenue falls faster than expected, the dividend could come under pressure. Pfizer has said explicitly that maintaining the dividend is a strategic priority — and large pharma companies fight hard to protect their payouts — but “priority” and “guaranteed” are different words.
Conclusion: A Reasonable Bet for Patient Dividend Investors — With Eyes Open
So, is Pfizer worth owning today for its dividend with the expectation of future growth? Tentatively, yes — but with a clear-eyed understanding of what you’re actually signing up for. You’re not buying a company whose growth is around the corner. You’re buying a company whose growth is likely several years away, supported by a deep but not-yet-monetized pipeline, while collecting a meaningful dividend yield along the way.
The Q1 earnings report showed an underlying commercial business performing better than the headline COVID-related declines suggest. The pipeline has genuine late-stage depth, and the legal wins on Vyndamax and COMIRNATY patent protection improve the cash flow picture post-2028 more than the market has perhaps appreciated. For someone dollar-cost averaging over the next 12 to 24 months, the current price range — near or below the 200-day moving average — is not an unreasonable place to accumulate. Just don’t expect a quick payoff. This is a 2028–2030 thesis with a dividend yield as a down payment.
